Stock Analysis
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Neurocrine Biosciences, Inc. (NBIX) stock analysis covering valuation, fundamentals, technical indicators, risk, AIQ Momentum, analyst catalysts, dividends, and the current AIQ Score.
Neurocrine Biosciences, Inc. (NBIX) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 79/100. Risk is the weakest current factor at 69/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
NBIX at a Glance
Crawlable current metrics from the latest market-close stock snapshot.
| Metric | Current |
|---|---|
| Price | $167.40 |
| AIQ Score | 74/100 |
| Overall View | Bullish |
| Technical Analysis Consensus | Strong Buy |
| Market Cap | $17.01B |
| P/E Ratio (TTM) | 24.02 |
| Forward P/E | — |
| EPS (Q3 FY2026) | $2.03 |
| Revenue (Q3 FY2026) | $1.12B |
| Dividend Yield (TTM) | 0.00% |
| Beta | 0.7 |
| Volume | 1.38M |
| 52-week range | $122.14-$186.12 |
| RSI 14 | 64.45 |
| 50-Day SMA | $148.58 |
| 200-Day SMA | $148.88 |
| Analyst Price Target | $206.80 |
| Next Earnings | Feb 10, 2027 |
NBIXNeurocrine Biosciences, Inc.
Healthcare / Biotechnology
Leader
Strong Relative Position
Latest quote
- Momentum70
- Value77
- Quality79
- Risk resilience69
- Sentiment—
NBIX Stock Analysis Summary
Neurocrine Biosciences, Inc. (NBIX) currently has an AIQ Score of 74/100, indicating a bullish setup. Quality is the strongest factor at 79/100. Risk resilience is the weakest current factor at 69/100. Technical, fundamental, catalyst, dividend, and risk evidence should be read together at the latest market-close snapshot.
In a bullish regime, NBIX has AIQ Score of 74/100 with Quality base of 79/100 and fading Risk resilience at 69/100. Wait for component alignment before adding exposure.
Healthcare · -1.18% stock move · NBIX classified in Biotechnology.
Current Evidence
AlgovestIQ Evidence Summary
Current consensus, supporting evidence, recent changes, and what would strengthen or weaken the view.
Is NBIX Bullish or Bearish Right Now?
NBIX currently has a bullish overall setup. Quality is the strongest factor at 79/100, while Risk Resilience is weakest at 69/100. The current evidence suggests a constructive setup.
- - Quality is supportive at 79/100.
- - Momentum is constructive at 70/100.
- - Risk Resilience is supportive at 69/100.
- - Price is +12.67% above its 50-day SMA.
- - Analyst target implies +23.54% upside from the latest quote.
- - No strong bearish evidence is available in the current snapshot.
Current Consensus
NBIX's Technical Analysis Consensus is currently Strong Buy, with 35 buy, 7 neutral, and 4 sell votes. NBIX's 14-day RSI is 64.45, which places the stock in a constructive momentum range. NBIX's beta is 0.7, indicating lower market sensitivity than the broad market.
What Changed in NBIX?
The largest recent change in NBIX is Momentum moving up by 9.0 points over the available 7-day comparison window. Quality remains the strongest visible factor.
What Would Change the NBIX Outlook?
The current bullish outlook could improve if AIQ reaches 65 (Bullish), momentum recovers, earnings revisions strengthen, and price confirms a stronger trend above the 50-day and 200-day moving averages. It would weaken if AIQ falls below 50 (Bearish), price loses long-term moving-average support, analyst expectations deteriorate, or risk evidence worsens.
AIQ 65+ (Bullish), RSI above 55, price above SMA-50/SMA-200, and positive catalyst or estimate-revision evidence.
AIQ below 50 (Bearish), RSI below 45, loss of SMA-200, negative revisions, or rising volatility and drawdown risk.
NBIX Decision Framework
Public evidence layers, setup checks, and risk context for Neurocrine Biosciences, Inc..
Neurocrine Biosciences, Inc. (NBIX) Stock Analysis
Neurocrine Biosciences, Inc. has an AIQ Score of 74/100 in a Bullish regime. Quality is strongest at 79/100. Beta is 0.7, below market sensitivity. Review the supporting stock factors together before drawing a conclusion from any single score.
| Evidence Layer | Public Evidence |
|---|---|
| Regime Context | NBIX is in a Bullish AIQ regime with score 74/100. |
| Signal Conflict | The primary conflict is that quality leads at 79/100 while risk lags at 69/100. |
| Factor Evidence | Momentum 70/100 · Value 77/100 · Quality 79/100 · Risk 69/100 |
| Persistence | Current snapshot evidence is shown; historical persistence remains in AIQ Pro. |
Current Setup Checklist
Quality is the strongest factor at 79/100.
Momentum is 70/100 and RSI (14) is 64.4.
NBIX is in a Bullish regime at 74/100.
Risk factor is 69/100 with beta 0.7 and annual volatility 35.22%.
Current conflict: quality leads at 79/100 while risk lags at 69/100.
NBIX Research Cluster
Ticker-specific paths for valuation, technical analysis, catalysts, dividends, financials, risk, and news.
NBIX Fundamentals
NBIX valuation, profitability, growth, margins, balance-sheet strength, and free cash flow.
NBIX Technical Analysis
NBIX technical setup based on RSI, MACD, moving averages, AIQ Momentum, volume, trend, volatility, and pivots.
NBIX Stock Catalysts
Track NBIX earnings, analyst ratings, price targets, estimate revisions, stock news, and upcoming events.
NBIX Dividend Analysis
NBIX dividend yield, annual dividend, payout ratio, payment history, and income reliability context.
NBIX Financial Data
NBIX revenue, earnings, income statement, balance sheet, cash flow, valuation ratios, and stock metrics.
NBIX Risk Analysis
NBIX volatility, beta, drawdown, Sharpe ratio, VaR, and downside resilience.
NBIX Stock News
NBIX stock news, market tone, recent headlines, and catalyst context.
NBIX vs Biotechnology Peers
Current peer cohort: NBIX · NKTR · NRIX · NVAX · OCUL. Compare AIQ, factor scores, Sharpe ratio and 1-year volatility in one indexable view.
| Peer | AIQ | Value | Momentum | Risk | Sharpe | 1Y Volatility | Compare |
|---|---|---|---|---|---|---|---|
| NBIX Current stock | 74/100 | 77/100 | 70/100 | 69/100 | 0.49 | 35.22% | Current |
| NKTR Nektar Therapeutics | 39/100 | 47/100 | 25/100 | 41/100 | -0.11 | 84.03% | NBIX vs NKTR |
| NRIX Nurix Therapeutics, Inc. | 65/100 | 94/100 | 50/100 | 40/100 | 0.64 | 67.30% | NBIX vs NRIX |
| NVAX Novavax, Inc. | — | — | 77/100 | 38/100 | 0.56 | 73.62% | NBIX vs NVAX |
| OCUL Ocular Therapeutix, Inc. | 38/100 | 41/100 | 34/100 | 36/100 | -0.45 | 76.10% | NBIX vs OCUL |
Peer cohort is resolved dynamically from the AlgovestIQ universe taxonomy and Compare relationship graph. Data as of Nov 13, 2026.
About the AIQ Score
Methodology for the current stock evidence.
The AlgovestIQ AIQ Score combines multiple dimensions of stock evidence, including momentum, valuation exposure, quality, risk resilience, sentiment context, and timing signals. It is a descriptive research score, not a guarantee of future performance or a personalized recommendation.
View AIQ methodologyFactor Diagnostics
A compact bridge from the AIQ score to the evidence tabs.
Open the return calculator with stock context while purchase price, shares, dates and fees remain user inputs.
Also for NBIX: historical return with reinvested dividends and stock average calculator for several buys.
AIQ Component Profile
Compare the five component scores on one consistent 0–100 scale.
Review earnings timing, revisions, news pressure, and prior event reactions in one place.
Open catalysts8 recent quarterly periods are available for review.
Checked Nov 16, 2026
Explore factor drivers, conflicts, persistence, and scenario sensitivity in the advanced workspace.
Fundamentals Verdict
Current snapshot fields are separate from reported-quarter statement tables.
Latest period Sep 30, 2026.
Market Confirmation
Technicals are summarized first, with the indicator library behind it.
Risk Alignment
Higher resilience is stronger; exposure metrics stay separate.
Continue Researching NBIX
Open the detailed evidence pages and workflows behind the stock overview read.
Premium Feature
Full AIQ Analysis
AIQ Intelligence
AIQ Pro for NBIX
Scenario Analysis
AIQ Scenario Builder
Portfolio Implication
Related Links
NBIX Stock FAQ
What is NBIX stock price today?
Neurocrine Biosciences, Inc.'s current stock price is $167.40. Use the live quote with AIQ Score, news, and risk context rather than treating price alone as a decision signal.
Is NBIX bullish or bearish right now?
NBIX's bullish or bearish read depends on the current AIQ Score, factor alignment, technical analysis consensus, valuation, risk, and catalyst evidence. A mixed setup should be treated differently from a broad confirmation across those signals.
What is NBIX's market cap?
NBIX's market cap is $17.01B based on the latest completed market-close snapshot from Nov 13, 2026. Use it with P/E ratio, revenue, and growth metrics to frame company size, valuation, and peer comparisons.
What is NBIX's current P/E ratio?
NBIX's current P/E ratio is 24.02 based on the latest completed market-close snapshot from Nov 13, 2026. Read it with revenue growth, margins, EPS, cash flow, and peer valuation rather than using P/E alone.
What is NBIX's RSI?
NBIX's 14-day RSI is 64.45 based on the latest completed market-close snapshot from Nov 13, 2026. RSI should be interpreted with MACD, moving averages, volume, volatility, and price trend.
Is NBIX above its 50-day and 200-day moving averages?
NBIX is 12.67% from its 50-day SMA and 12.44% from its 200-day SMA based on the latest completed market-close snapshot from Nov 13, 2026. Moving-average position should be read with momentum and broader AIQ evidence.
When is NBIX's next earnings date?
NBIX's next earnings date is currently listed as Feb 10, 2027. Earnings can reset revenue, EPS, price target, analyst rating, and catalyst expectations.
Does NBIX pay a dividend?
NBIX's dividend yield is 0.00% based on the latest completed market-close snapshot from Nov 13, 2026. Dividend yield should be read with payout ratio, free cash flow, growth, and balance-sheet strength.